KRT6A and non-small cell lung carcinoma: And our study showed that NSCLC patients with different inflammatory-related gene risk-score is the potential biomarker used in chemotherapy and immunotherapy, and targeting KRT6A sensitive to mitoxantrone and oxaliplatin in NSCLC.